LU92397I2 - Vortioxétine ou un sel d'addition d'acide de celui-ci pharmaceutiquement acceptable - Google Patents

Vortioxétine ou un sel d'addition d'acide de celui-ci pharmaceutiquement acceptable

Info

Publication number: LU92397I2
Authority: LU; Luxembourg
Prior art keywords: vortioxetine; pharmaceutically acceptable; acid addition; addition salt; acceptable acid
Prior art date: 2001-10-04

Application number

LU92397C

Other languages

English (en)

Original Assignee

Lundbeck & Co As H

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-10-04

Filing date

2014-03-12

Publication date

2014-05-12

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8160750&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92397(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-03-12 Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H

2014-05-12 Publication of LU92397I2 publication Critical patent/LU92397I2/fr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
- C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
- C07D295/033—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Hydrogenated Pyridines (AREA)
Plural Heterocyclic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

LU92397C 2001-10-04 2014-03-12 Vortioxétine ou un sel d'addition d'acide de celui-ci pharmaceutiquement acceptable LU92397I2 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DKPA200101466		2001-10-04

Publications (1)

Publication Number	Publication Date
LU92397I2 true LU92397I2 (fr)	2014-05-12

Family

ID=8160750

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU92397C LU92397I2 (fr)	2001-10-04	2014-03-12	Vortioxétine ou un sel d'addition d'acide de celui-ci pharmaceutiquement acceptable

Country Status (38)

Country	Link
US (10)	US7144884B2 (fr)
EP (2)	EP1436271B3 (fr)
JP (3)	JP3896116B2 (fr)
KR (3)	KR100770194B1 (fr)
CN (1)	CN1319958C (fr)
AR (2)	AR036659A1 (fr)
AT (2)	ATE441631T1 (fr)
AU (2)	AU2002333220C1 (fr)
BE (1)	BE2014C036I2 (fr)
BR (3)	BR122012023120B8 (fr)
CA (1)	CA2462110C (fr)
CO (1)	CO5580746A2 (fr)
CY (3)	CY1107924T1 (fr)
DE (2)	DE60233608D1 (fr)
DK (2)	DK1436271T6 (fr)
EA (2)	EA011096B1 (fr)
EG (1)	EG25095A (fr)
ES (2)	ES2298425T7 (fr)
FR (1)	FR14C0033I2 (fr)
HR (1)	HRP20040220A2 (fr)
HU (3)	HU228956B1 (fr)
IL (1)	IL160655A0 (fr)
IS (2)	IS2578B (fr)
LT (1)	LTC1436271I2 (fr)
LU (1)	LU92397I2 (fr)
ME (1)	ME00039B (fr)
MX (1)	MXPA04002959A (fr)
MY (1)	MY140950A (fr)
NL (1)	NL300652I1 (fr)
NO (3)	NO326443B1 (fr)
NZ (1)	NZ531556A (fr)
PL (2)	PL209253B1 (fr)
PT (2)	PT1749818E (fr)
RS (2)	RS52865B (fr)
SI (1)	SI1436271T1 (fr)
UA (2)	UA81749C2 (fr)
WO (1)	WO2003029232A1 (fr)
ZA (1)	ZA200401583B (fr)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA81749C2 (uk)	2001-10-04	2008-02-11	Х. Луннбек А/С	Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
GB0305575D0 (en) *	2003-03-11	2003-04-16	Glaxo Group Ltd	Novel compounds
HRP20080478T3 (hr) *	2003-04-04	2009-02-28	H. Lundbeck A/S	Derivati 4-(2-fenilsulfanil-fenil)-piperidina kaoinhibitori ponovne pohrane serotonina
UA81300C2 (en) *	2003-04-04	2007-12-25	Lundbeck & Co As H	Derivates of 4-(2-fenilsulfanilfenil)-1,2,3,6-tetrahydropiridin as retarding agents of serotonin recapture
EA010869B1 (ru) *	2003-04-04	2008-12-30	Х. Лундбекк А/С	Производные 4-(2-фенилсульфанилфенил)пиперидина в качестве ингибиторов повторного поглощения серотонина
PT1635828E (pt) *	2003-04-04	2008-07-01	Lundbeck & Co As H	Derivados de 4-(2-feniloxifenil) piperidina ou de 1,2,3,6-tetrahidropiridina como inibidores da recaptação da serotonina
ZA200505031B (en) *	2003-04-04	2006-09-27	Lundbeck & Co As H	4-(2-Phenyloxyphenyl)-piperidine or -1,2,3,6-tetrahy-dropyridine derivatives as serotonin reuptake inhibitors
RS50589B (sr)	2003-12-23	2010-05-07	H. Lundbeck A/S.	2-(1h-indolilsulfanil)-benzil amin derivati kao ssri
AR052308A1 (es) *	2004-07-16	2007-03-14	Lundbeck & Co As H	Derivados de 2-(1h-indolilsulfanil)-arilamina y una composicion farmaceutica que contiene al compuesto
US7923444B2 (en) *	2005-02-10	2011-04-12	Neurosearch A/S	Alkyl substituted homopiperazine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
AR054393A1 (es)	2005-06-17	2007-06-20	Lundbeck & Co As H	Derivados de benzo(b)furano y benzo(b)tiofeno, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de la reabsorcion de neurotransmisores de amina biogenicos.
US7629473B2 (en)	2005-06-17	2009-12-08	H. Lundbeck A/S	2-(1H-indolylsulfanyl)-aryl amine derivatives
AR054394A1 (es) *	2005-06-17	2007-06-20	Lundbeck & Co As H	Derivados de 2- (1h-indolilsulfanil)-aril amina
JP2007106746A (ja) *	2005-09-13	2007-04-26	Tosoh Corp	新規アリールホモピペラジン類、またはその塩と製造方法
CA2656057C (fr)	2006-06-16	2012-10-02	H. Lundbeck A/S	Formes cristallines de la 4-[2-(4-methylphenylsulfanyl)-phenyl] piperidine avec inhibition de la reabsorption de la serotonine et de la norepinephrine en combinaison pour le traitement de la douleur neuropathique
ZA200809917B (en) *	2006-06-16	2010-08-25	Lundbeck & Co As H	Crystalline forms of 4- [2-(4-Methylphenylsulfanyl) - Phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
JP7179035B2 (ja) *	2006-06-16	2022-11-28	ハー・ルンドベック・アクチエゼルスカベット	認識機能障害（ｃｏｇｎｉｔｉｖｅｉｍｐａｉｒｍｅｎｔ）を治療するための、組み合わされたセロトニン再取り込み、５－ＨＴ３および５－ＨＴ１Ａ活性を有する化合物としての１－［２－（２，４－ジメチルフェニルスルファニル）－フェニル］ピペラジン
ATE508115T1 (de) *	2006-06-16	2011-05-15	Lundbeck & Co As H	Kristalline formen von 4-ä2-(4- methylphenylsulfanyl)phenylüpiperidin mit kombinierter serotonin- und norepinephrinwiederaufnahmehemmung zur behandlung neuropathischer schmerzen
KR20090028712A (ko) *	2006-06-16	2009-03-19	하. 룬트벡 아크티에 셀스카브	인지기능 장애의 치료를 위한, 세로토닌 재흡수, 5-ｈｔ3 및 5-ｈｔ1ａ 활성이 조합된 화합물로서의 1-[2-(2,4-디메틸페닐술파닐)-페닐]피페라진
TW200848411A (en) *	2007-03-20	2008-12-16	Lundbeck & Co As H	Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine
TWI405588B (zh) *	2007-03-20	2013-08-21	Lundbeck & Co As H	４-〔２-（４-甲苯基硫基）-苯基〕哌啶之鹽類的液體調配物
TWI432194B (zh) *	2007-03-20	2014-04-01	Lundbeck & Co As H	４-〔２-（４-甲基苯硫基）苯基〕哌啶之新穎治療用途
HRP20140044T1 (hr) *	2007-06-15	2014-02-14	H. Lundbeck A/S	4-[2-(4-metilfenilsulfanil)fenil]piperidin za lijeäśenje iritabilnog sindroma crijeva (ibs)
TW200932233A (en) *	2007-11-13	2009-08-01	Lundbeck & Co As H	Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
AU2014200364B2 (en) *	2007-11-13	2015-09-17	H. Lundbeck A/S	Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1A activity
TW200932225A (en) *	2007-12-14	2009-08-01	Lundbeck & Co As H	4-[2,3-difluoro-6-(2-fluoro-4-methyl-phenylsulfanyl)-phenyl]-piperidine
TW200938194A (en) *	2007-12-14	2009-09-16	Lundbeck & Co As H	Therapeutic uses of compounds having affinity to the serotonin transporter, serotonin receptors and noradrenalin transporter
WO2009081259A1 (fr) *	2007-12-21	2009-07-02	Pfizer Inc.	Dérivés phénoxy-pyridylés
UA98698C2 (en) *	2008-03-03	2012-06-11	Х. Луннбек А/С	Phenylsulfanylphenyl-piperidines and process for the preparation thereof
PT2358675E (pt)	2008-11-14	2012-12-12	Theravance Inc	Compostos de 4-[2-(2-fluorofenoximetil)fenil]piperidina
TW201033181A (en) *	2009-02-17	2010-09-16	Lundbeck & Co As H	Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine
EP2421534B1 (fr)	2009-04-24	2014-09-03	H. Lundbeck A/S	Formulations liquides de sels de 1-[2-(2,4-diméthylphénylsulfanyl)- phényl]pipérazine
JP2013502446A (ja)	2009-08-24	2013-01-24	ハー・ルンドベック・アクチエゼルスカベット	１−［２−（２，４−ジメチル−フェニルスルファニル）−フェニル］ピペラジンの新規組成物
AU2010313402B2 (en) *	2009-10-30	2015-12-03	Janssen Pharmaceutica Nv	4-substituted-2-phenoxy-phenylamine delta opioid receptor modulators
US8778949B2 (en) *	2010-01-11	2014-07-15	Theravance Biopharma R&D Ip, Llc	1-(2-phenoxymethylphenyl)piperazine compounds
ES2543064T3 (es) *	2010-03-22	2015-08-14	Theravance Biopharma R&D Ip, Llc	Compuestos de 1-(2-fenoximetilheteroaril)piperidina y piperazina
RU2593771C2 (ru)	2010-04-30	2016-08-10	Такеда Фармасьютикал Компани Лимитед	Энтеросолюбильная таблетка
BR112012027794A2 (pt) *	2010-04-30	2016-08-02	Takeda Pharmaceutical	tablete entérico
EP2407467A1 (fr)	2010-07-14	2012-01-18	Sandoz Ag	Composés cristallins de 1-[4-(2-azépan-1-yl-éthoxy)-benzyl]-2-(4-hydroxyphényl)-3-méthyl-1H-indol-5-ol et d'acide lactique
TW201212918A (en)	2010-08-23	2012-04-01	Lundbeck & Co As H	Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
SI3135656T1 (sl)	2011-06-20	2019-05-31	H. Lundbeck A/S	Devterirani 1-piperazino-3-fenil indani za zdravljenje shizofrenije
EP2780467B1 (fr)	2011-11-14	2018-10-17	Alfasigma S.p.A.	Dosages et procédés pour la sélection d'un schéma thérapeutique pour un sujet atteint d'une dépression
EP2800746B1 (fr) *	2012-01-03	2019-04-17	H. Lundbeck A/S	Procédé de fabrication de 1- [2- (2,4-diméthyl-phénylsulfanyl)-phényl]-pipérazine
BR112015006075B1 (pt)	2012-09-19	2022-10-04	Sandoz Ag	Composto cristalino, composição farmacêutica, uso do composto cristalino, hidrato cristalino do bromidrato de vortioxetina, método para a preparação do hidrato cristalino de bromidrato de vortioxetina, método para a preparação do composto cristalino e uso do hidrato cristalino de bromidrato de vortioxetina
CN104853755B (zh)	2012-12-13	2017-08-22	H.隆德贝克有限公司	包含沃替西汀和多奈哌齐的组合物
RS55932B1 (sr) *	2013-02-22	2017-09-29	H Lundbeck As	Postupak za proizvodnju vortioksetina
SI2981520T1 (sl) *	2013-04-04	2019-07-31	Lek Pharmaceuticals D.D.	Novi proces za sintezo 1-(2-((2,4-dimetilfenil)tio)fenil)piperazina
CN104109135B (zh) *	2013-04-22	2018-10-26	江苏豪森药业集团有限公司	1-[2-(2,4-二甲基苯基硫烷基)-苯基]哌嗪的制备方法
US10414741B2 (en)	2013-09-30	2019-09-17	Cadila Healthcare Limited	Amorphous vortioxetine and salts thereof
EP2878596A1 (fr) *	2013-11-29	2015-06-03	LEK Pharmaceuticals d.d.	Synthèse de vortioxetine via des intermédiaires de (2-(pipérazine-1-yl)phényl)lithium
CN104710345B (zh) *	2013-12-17	2017-09-05	江苏恩华药业股份有限公司	用于制备4‑（2‑（4‑甲基苯基硫基））苯基哌啶的化合物、其制备方法及应用
JP6448645B2 (ja)	2013-12-20	2019-01-09	ハー・ルンドベック・アクチエゼルスカベット	メランコリアの特徴を伴う抑うつ障害を処置するための、カッパ−活性を伴うオピオイド受容体拮抗薬およびボルチオキセチンの使用
EP2894154A1 (fr)	2014-01-14	2015-07-15	LEK Pharmaceuticals d.d.	Synthèse de vortioxetine via des intermédiaires de (2-(piperazine-1-yl)phényl)aniline
CN103788019B (zh) *	2014-01-22	2015-10-07	苏州明锐医药科技有限公司	沃替西汀的制备方法
EA029060B1 (ru)	2014-01-31	2018-02-28	Эгиш Дьёдьсердьяр Зрт.	Способ получения солей вортиоксетина
EP2930171A1 (fr)	2014-04-07	2015-10-14	LEK Pharmaceuticals d.d.	Synthèse de vortioxetine via intermédiaire de (2,4-diméthylphényl) (2-iodophényl)sulfane
CN104059030B (zh) *	2014-05-30	2016-05-04	镇江圣安医药有限公司	[(苯硫烷基)-苯基]哌嗪的衍生物及其药物组合物和用途
FR3023320B1 (fr) *	2014-07-03	2017-03-10	Ifp Energies Now	Systeme et procede de stockage et de recuperation d'energie par gaz comprime avec stockage de la chaleur au moyen d'un echangeur radial
CZ2014471A3 (cs)	2014-07-08	2016-01-20	Zentiva, K.S.	Způsob přípravy vortioxetinu
US9687484B2 (en)	2014-07-18	2017-06-27	Dipharma Francis S.R.L.	Crystalline forms of an antidepressant compound
CN104146953A (zh) *	2014-07-24	2014-11-19	李雪梅	一种氢溴酸沃替西汀注射液
CN104292183B (zh) *	2014-09-29	2016-01-06	杨献美	一种抗抑郁药物沃替西汀的制备方法
WO2016079751A2 (fr)	2014-11-17	2016-05-26	Megafine Pharma (P) Ltd.	Procédé de préparation de vortioxétine et de polymorphes de cette substance
ES2634496T3 (es)	2014-11-21	2017-09-28	Dipharma Francis S.R.L.	Proceso para la preparación de un antidepresivo y los intermedios del mismo
CN104447622B (zh) *	2014-11-28	2017-01-04	郑州大明药物科技有限公司	氢溴酸沃替西汀β晶型的制备方法
CN104586756A (zh) *	2015-01-05	2015-05-06	万特制药(海南)有限公司	一种含沃替西汀的口服溶液及其制备方法
CZ201531A3 (cs)	2015-01-21	2016-08-03	Zentiva, K.S.	Polymerem stabilizované amorfní formy vortioxetinu
CN104610195B (zh) *	2015-01-30	2017-06-27	上虞京新药业有限公司	沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途
WO2016125191A2 (fr)	2015-02-04	2016-08-11	Mylan Laboratories Limited	Procédés de préparation de bromhydrate de vortioxétine
WO2016125190A2 (fr)	2015-02-04	2016-08-11	Mylan Laboratories Limited	Nouvelles formes cristallines de vortioxétine, prémélanges, et procédés pour la préparation de ceux-ci
AU2016224930A1 (en)	2015-02-25	2017-09-07	Lupin Limited	Process for the preparation of Vortioxetine
EP3274330A1 (fr)	2015-03-26	2018-01-31	Cipla Limited	Procédé de fabrication d'inhibiteurs de la recapture de la sérotonine
CN104829557B (zh) *	2015-04-23	2017-06-27	山东百诺医药股份有限公司	一种新化合物1‑[2‑（2,4‑二甲基苯基硫基）苯基]‑2‑氧哌嗪及其制备方法和在沃替西汀合成中的应用
JO3456B1 (ar)	2015-05-13	2020-07-05	H Lundbeck As	فيروتيوكسيتين بيروجلوتامات
EP3324952B1 (fr)	2015-07-17	2020-12-16	Institut Pasteur	Agent récepteur-stimulant 5-hydroxytryptamine1b destiné à être utilisé comme promoteur de l'autorenouvellement de cellules et/ou la différenciation par satellite
WO2017029377A1 (fr) *	2015-08-19	2017-02-23	Amneal Pharmaceuticals Company Gmbh	Procédé de préparation de bromhydrate de vortioxétine
EP3362058B1 (fr) *	2015-10-14	2021-09-01	Institut Pasteur	Agent de stimulation du récepteur 5-hydroxytryptamine 1b pour le traitement de l'infarctus du myocarde
CN105348204B (zh) *	2015-11-18	2018-09-14	乳源瑶族自治县大众药品贸易有限公司	1-杂环基-2-(杂芳基硫基)苯衍生物及其使用方法和用途
CN105461635B (zh) *	2015-11-18	2018-06-08	乳源瑶族自治县大众药品贸易有限公司	苯基哌嗪衍生物及其使用方法和用途
US11013830B2 (en)	2015-11-20	2021-05-25	Institut Pasteur	5-hydroxytryptamine 1B receptor-stimulating agent for enhancing in vivo engraftment potential
WO2017162536A1 (fr)	2016-03-21	2017-09-28	H. Lundbeck A/S	Promédicaments de vortioxétine
JP2019524682A (ja)	2016-07-01	2019-09-05	ハー・ルンドベック・アクチエゼルスカベット	抗うつ作用の速い発現のためのボルチオキセチン投与計画
WO2018011382A1 (fr)	2016-07-15	2018-01-18	Institut Pasteur	Agent stimulant le récepteur de la 5-hydroxytryptamine 1b pour la réparation de la peau et/ou des cheveux.
EP3489225A4 (fr) *	2016-07-22	2019-12-18	Jiangsu Nhwaluokang Pharmaceutical Research and Development Co., Ltd.	Analogue de vortioxétine, son utilisation et sa préparation
US20190224192A1 (en)	2016-08-29	2019-07-25	Cipla Limited	Stable Pharmaceutical Composition of Vortioxetine Hydrobromide
CN106349132B (zh) *	2016-08-30	2018-02-02	重庆植恩药业有限公司	沃替西汀中间体杂质及其制备方法和用途
US10519121B2 (en)	2016-12-30	2019-12-31	Apicore Us Llc	Process and novel polymorphic form of vortioxetine and its pharmaceutically acceptable salts
CN108409728B (zh) *	2017-02-09	2020-11-24	广东东阳光药业有限公司	苯基八氢-1H-吡啶并[1,2-a]吡嗪衍生物及其用途
CN108409729B (zh) *	2017-02-09	2020-11-24	广东东阳光药业有限公司	苯基八氢-1H-吡啶并[1,2-a]吡嗪衍生物及其用途
US10428033B2 (en)	2017-02-15	2019-10-01	Piramal Enterprises Limited	Process for the preparation of vortioxetine and salts thereof
US11020390B2 (en)	2017-02-17	2021-06-01	Unichem Laboratories Ltd	Bioequivalent pharmaceutical composition of vortioxetine hydrobromide
US10836730B2 (en)	2017-02-23	2020-11-17	Unichem Laboratories Ltd.	Process for preparation and purification of vortioxetine hydrobromide
JP7121751B2 (ja) *	2017-04-25	2022-08-18	ハー・ルンドベック・アクチエゼルスカベット	ボルチオキセチンＨＢｒ α型を製造するための方法
EP3412661A1 (fr)	2017-06-08	2018-12-12	Enantia, S.L.	Co-cristaux de bromhydrate vortioxetine et du résorcinol
KR102026337B1 (ko)	2017-07-07	2019-09-27	영진약품 주식회사	1-[2-(2,4-디메틸페닐설파닐)페닐]피페라진의 신규염 및 이의 제조방법
CN107915685A (zh) *	2017-12-11	2018-04-17	重庆植恩药业有限公司	一种氢溴酸沃替西汀中间体的制备方法
CN108017595A (zh) *	2017-12-20	2018-05-11	安徽源久源科技有限公司	一种1-[2-(2,5-二甲基苯硫基)苯基]哌嗪的制备方法
EP3810582B1 (fr)	2018-06-20	2024-01-03	Vio Ag Pharmaceuticals S.A.	Approche d'activation c-h organo-pseudocatalytique monotope pour la préparation de vortioxétine et intermédiaire de vortioxétine
CN108727393B (zh) *	2018-08-06	2019-10-29	广东东阳光药业有限公司	苯基二氮杂双环衍生物及其用途
CN108863986B (zh) *	2018-08-06	2020-01-21	广东东阳光药业有限公司	二氟甲基取代的苯基哌嗪衍生物及其用途
EP3870292A4 (fr)	2018-10-26	2022-11-09	The Research Foundation for The State University of New York	Combinaison d'un inhibiteur de réabsorption spécifique de la sérotonine et d'un agoniste partiel du récepteur de la sérotonine 1a pour réduire la dyskinésie induite par l-dopa
KR20220163997A (ko)	2020-04-03	2022-12-12	하. 룬드벡 아크티에셀스카브	정서적 둔마의 예방 또는 치료를 위한 1-[2-(2,4-디메틸페닐설파닐)-페닐]피페라진
US12281088B2 (en)	2020-09-10	2025-04-22	Suzhou Fude Zhaofeng Biochemical Technology Co., Ltd	Process for the synthesis of vortioxetine
GB2622880A (en)	2022-09-30	2024-04-03	Alkaloid Ad Skopje	Palatable orodispersible formulation of vortioxetine
WO2025132869A1 (fr)	2023-12-21	2025-06-26	H. Lundbeck A/S	Procédé de préparation de compositions pharmaceutiques de vortioxétine présentant de faibles quantités d'impuretés de nitrosamine
CN120774863A (zh) *	2024-04-02	2025-10-14	王春刚	一种烷基二胺取代双芳杂环基硫醚类化合物及其制备和在制备治疗和/或预防肿瘤药物中的应用
EP4681702A1 (fr)	2024-07-16	2026-01-21	PharmaPath S.A.	Solution orale comprenant hydrobromure de vortioxétine

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CS151752B1 (fr)	1971-04-13	1973-11-19
CS151755B1 (fr)	1971-04-13	1973-11-19
CS151751B1 (fr)	1971-04-13	1973-11-19
CS151753B1 (fr)	1971-04-13	1973-11-19
YU163075A (en)	1975-07-21	1982-05-31	Science Union & Cie	Process for preparing new phenoxy derivatives
US4241071A (en)	1977-01-27	1980-12-23	American Hoechst Corporation	Antidepressant (α-phenyl-2-tolyl)azacycloalkanes
US4198417A (en)	1979-01-10	1980-04-15	American Hoechst Corporation	Phenoxyphenylpiperidines
US4198419A (en)	1979-01-10	1980-04-15	American Hoechst Corporation	Phenylthiophenylpiperidines
ES2004809A6 (es)	1987-07-29	1989-02-01	Ferrer Int	Procedimiento de obtencion de nuevas 1-(2-(fenilmetil)fenil)piperazinas
GB9126311D0 (en)	1991-12-11	1992-02-12	Wellcome Found	Substituted diphenylsulfides
EP0755923B1 (fr) *	1995-01-23	2005-05-04	Daiichi Suntory Pharma Co., Ltd.	Ameliorant ou remede contre des symptomes provoques par des maladies ischemiques et composes phenylpiperidiniques utiles a cet effet
CZ293595A3 (cs)	1995-11-09	1999-12-15	Farmak A. S.	Deriváty N,N-dimethyl-2-(arylthio)benzylaminu, jejich soli, způsoby jejich přípravy a jejich použití v léčivých přípravcích
FR2757160B1 (fr) *	1996-12-13	1999-03-12	Sanofi Sa	1-phenylalkyl-1,2,3,6-tetrahydropyridines
US6297239B1 (en)	1997-10-08	2001-10-02	Merck & Co., Inc.	Inhibitors of prenyl-protein transferase
DE69828317T2 (de) *	1997-10-31	2005-05-25	Daiichi Suntory Pharma Co., Ltd.	Verfahren zur Herstellung von N-((4-Phenyl)methylphenyl)piperazinen
CA2369005A1 (fr)	1999-04-02	2000-10-12	Icos Corporation	Inhibiteurs de la liaison de lfa-1 a des icams icams et lieurs utilisations
CA2381008A1 (fr)	1999-08-04	2001-02-15	Millennium Pharmaceuticals, Inc.	Composes fixant les recepteurs de melanocortine-4 et procedes d'utilisation de ces composes
AU766592B2 (en) *	1999-09-14	2003-10-16	Pharmacopeia, Inc.	Article comprising a multi-channel dispensing head
AU2351701A (en) *	1999-12-30	2001-07-16	H. Lundbeck A/S	A method for the preparation of substituted benzene derivatives
PL199351B1 (pl) *	1999-12-30	2008-09-30	Lundbeck & Co As H	Związki pochodne fenylopiperazyny, zawierająca je kompozycja farmaceutyczna i ich zastosowanie
US6813639B2 (en)	2000-01-26	2004-11-02	Viaclix, Inc.	Method for establishing channel-based internet access network
DE10033548C2 (de)	2000-07-11	2002-05-16	Wolfgang Papenbrock	Verfahren zur Vorschau von Internetseiten
CA2432985A1 (fr) *	2001-01-23	2002-08-01	Vincent Mancuso	Derives de piperazine et de piperidine en tant qu'agonistes du recepteur de la melanocortine
EP1363890A4 (fr)	2001-02-07	2009-06-10	Ore Pharmaceuticals Inc	Composes de liaison au recepteur de la melanocortine-4 et procedes d'utilisation de tels composes
UA81749C2 (uk)	2001-10-04	2008-02-11	Х. Луннбек А/С	Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
MXPA04005989A (es) *	2001-12-20	2004-09-27	Lundbeck & Co As H	Derivados de ariloxifenilo y arilsulfanilfenilo.
TW200505902A (en)	2003-03-20	2005-02-16	Schering Corp	Cannabinoid receptor ligands
HRP20080478T3 (hr) *	2003-04-04	2009-02-28	H. Lundbeck A/S	Derivati 4-(2-fenilsulfanil-fenil)-piperidina kaoinhibitori ponovne pohrane serotonina
WO2005000309A2 (fr)	2003-06-27	2005-01-06	Ionix Pharmaceuticals Limited	Composes chimiques
KR20090028712A (ko) *	2006-06-16	2009-03-19	하. 룬트벡 아크티에 셀스카브	인지기능 장애의 치료를 위한, 세로토닌 재흡수, 5-ｈｔ3 및 5-ｈｔ1ａ 활성이 조합된 화합물로서의 1-[2-(2,4-디메틸페닐술파닐)-페닐]피페라진

2002
- 2002-02-10 UA UA2004032271A patent/UA81749C2/uk unknown
- 2002-09-30 AR ARP020103689A patent/AR036659A1/es active IP Right Grant
- 2002-10-02 HU HU0402313A patent/HU228956B1/hu active Protection Beyond IP Right Term
- 2002-10-02 EA EA200601269A patent/EA011096B1/ru not_active IP Right Cessation
- 2002-10-02 BR BR122012023120A patent/BR122012023120B8/pt active IP Right Grant
- 2002-10-02 MX MXPA04002959A patent/MXPA04002959A/es active IP Right Grant
- 2002-10-02 BR BRPI0212733A patent/BRPI0212733B8/pt active IP Right Grant
- 2002-10-02 EP EP02800051.1A patent/EP1436271B3/fr not_active Expired - Lifetime
- 2002-10-02 SI SI200230678T patent/SI1436271T1/sl unknown
- 2002-10-02 CN CNB028190254A patent/CN1319958C/zh not_active Expired - Lifetime
- 2002-10-02 ES ES02800051T patent/ES2298425T7/es active Active
- 2002-10-02 KR KR1020047004897A patent/KR100770194B1/ko not_active Expired - Lifetime
- 2002-10-02 BR BR122012009534D patent/BR122012009534C8/pt not_active IP Right Cessation
- 2002-10-02 RS RS20120158A patent/RS52865B/sr unknown
- 2002-10-02 EG EG2002101084A patent/EG25095A/xx active
- 2002-10-02 EP EP06016609A patent/EP1749818B1/fr not_active Expired - Lifetime
- 2002-10-02 HU HU1300028A patent/HU230189B1/hu unknown
- 2002-10-02 KR KR1020067022562A patent/KR100783346B1/ko not_active Expired - Lifetime
- 2002-10-02 DE DE60233608T patent/DE60233608D1/de not_active Expired - Lifetime
- 2002-10-02 NZ NZ531556A patent/NZ531556A/en not_active IP Right Cessation
- 2002-10-02 PL PL368442A patent/PL209253B1/pl unknown
- 2002-10-02 PT PT06016609T patent/PT1749818E/pt unknown
- 2002-10-02 PT PT02800051T patent/PT1436271E/pt unknown
- 2002-10-02 AT AT06016609T patent/ATE441631T1/de active
- 2002-10-02 HR HR20040220A patent/HRP20040220A2/hr not_active Application Discontinuation
- 2002-10-02 UA UAA200612495A patent/UA93857C2/uk unknown
- 2002-10-02 CA CA2462110A patent/CA2462110C/fr not_active Expired - Lifetime
- 2002-10-02 DK DK02800051.1T patent/DK1436271T6/da active
- 2002-10-02 RS YU27704A patent/RS52326B/sr unknown
- 2002-10-02 DE DE60225162.1T patent/DE60225162T3/de not_active Expired - Lifetime
- 2002-10-02 WO PCT/DK2002/000659 patent/WO2003029232A1/fr not_active Ceased
- 2002-10-02 KR KR1020077022025A patent/KR100842702B1/ko not_active Expired - Lifetime
- 2002-10-02 AU AU2002333220A patent/AU2002333220C1/en active Active
- 2002-10-02 EA EA200400498A patent/EA007537B3/ru active Protection Beyond IP Right Term
- 2002-10-02 JP JP2003532482A patent/JP3896116B2/ja not_active Expired - Lifetime
- 2002-10-02 ME MEP-2008-65A patent/ME00039B/fr unknown
- 2002-10-02 DK DK06016609T patent/DK1749818T3/da active
- 2002-10-02 PL PL392184A patent/PL210551B1/pl unknown
- 2002-10-02 AT AT02800051T patent/ATE386730T1/de active
- 2002-10-02 US US10/488,280 patent/US7144884B2/en active Active
- 2002-10-02 IL IL16065502A patent/IL160655A0/xx active Protection Beyond IP Right Term
- 2002-10-02 ES ES06016609T patent/ES2328725T3/es not_active Expired - Lifetime
- 2002-10-03 MY MYPI20023705A patent/MY140950A/en unknown
2004
- 2004-02-26 IS IS7164A patent/IS2578B/is unknown
- 2004-02-26 ZA ZA2004/01583A patent/ZA200401583B/en unknown
- 2004-04-21 NO NO20041628A patent/NO326443B1/no active IP Right Maintenance
- 2004-04-30 CO CO04039958A patent/CO5580746A2/es not_active Application Discontinuation
2005
- 2005-12-06 US US11/296,836 patent/US7148238B2/en not_active Expired - Lifetime
- 2005-12-06 US US11/296,835 patent/US7138407B2/en not_active Expired - Lifetime
2006
- 2006-09-14 AU AU2006215994A patent/AU2006215994B2/en not_active Ceased
- 2006-10-03 JP JP2006271758A patent/JP3955613B2/ja not_active Expired - Lifetime
- 2006-10-03 JP JP2006271762A patent/JP3955614B2/ja not_active Expired - Lifetime
- 2006-10-19 US US11/551,188 patent/US7683053B2/en not_active Expired - Fee Related
2008
- 2008-04-18 CY CY20081100436T patent/CY1107924T1/el unknown
- 2008-05-06 AR ARP080101915A patent/AR066460A2/es active IP Right Grant
- 2008-08-06 NO NO20083446A patent/NO332355B1/no not_active IP Right Cessation
2009
- 2009-03-10 IS IS8806A patent/IS2732B/is unknown
- 2009-10-14 CY CY20091101068T patent/CY1110064T1/el unknown
2010
- 2010-02-04 US US12/700,521 patent/US8110567B2/en not_active Expired - Fee Related
2012
- 2012-02-06 US US13/367,065 patent/US8476279B2/en not_active Expired - Fee Related
2013
- 2013-06-26 US US13/927,678 patent/US9090575B2/en not_active Expired - Fee Related
2014
- 2014-03-07 NL NL300652C patent/NL300652I1/nl unknown
- 2014-03-12 HU HUS1400012C patent/HUS1400012I1/hu unknown
- 2014-03-12 LU LU92397C patent/LU92397I2/fr unknown
- 2014-03-13 LT LTPA2014013C patent/LTC1436271I2/lt unknown
- 2014-04-16 FR FR14C0033C patent/FR14C0033I2/fr active Active
- 2014-05-13 NO NO2014011C patent/NO2014011I2/no not_active IP Right Cessation
- 2014-06-03 BE BE2014C036C patent/BE2014C036I2/nl unknown
- 2014-06-11 CY CY2014022C patent/CY2014022I1/el unknown
2015
- 2015-06-19 US US14/744,197 patent/US9708280B2/en not_active Expired - Fee Related
2017
- 2017-06-15 US US15/624,417 patent/US10844029B2/en not_active Expired - Fee Related
2020
- 2020-10-22 US US17/078,055 patent/US20210276966A1/en not_active Abandoned

Also Published As

Publication number	Publication date
HK1072600A1 (zh)	2005-09-02
IS8806A (is)	2009-03-10
HUS1400012I1 (hu)	2020-12-28
CY2014022I2 (el)	2015-12-09
DE60225162T2 (de)	2009-02-12
FR14C0033I1 (fr)	2014-06-13
US20070060574A1 (en)	2007-03-15
BR122012009534B8 (pt)	2019-01-29
BR0212733A (pt)	2004-11-16
IS2732B (is)	2011-04-15
EP1749818A3 (fr)	2008-04-02
AU2002333220A2 (en)	2003-04-14
MEP6508A (xx)	2010-02-10
KR100770194B1 (ko)	2007-10-25
ES2298425T7 (es)	2022-06-27
CA2462110C (fr)	2010-05-11
HU228956B1 (en)	2013-07-29
MY140950A (en)	2010-02-12
CN1561336A (zh)	2005-01-05
US7144884B2 (en)	2006-12-05
EA007537B3 (ru)	2015-02-27
DK1436271T3 (da)	2008-06-09
UA93857C2 (uk)	2011-03-25
US20140163043A1 (en)	2014-06-12
AU2006215994B2 (en)	2008-11-13
EA200400498A1 (ru)	2004-08-26
JP2007051149A (ja)	2007-03-01
HUP0402313A3 (en)	2010-03-29
CY2014022I1 (el)	2015-12-09
EA200601269A1 (ru)	2007-02-27
BR122012009534B1 (pt)	2018-02-27
ES2298425T3 (es)	2008-05-16
NO326443B1 (no)	2008-12-08
KR100783346B1 (ko)	2007-12-07
LTPA2014013I1 (lt)	2014-04-25
ATE441631T1 (de)	2009-09-15
RS20120158A2 (sr)	2012-10-31
ME00039B (fr)	2010-06-10
IL160655A0 (en)	2004-07-25
US20160137620A1 (en)	2016-05-19
US7138407B2 (en)	2006-11-21
BR122012023120B1 (pt)	2017-03-21
AU2006215994A1 (en)	2006-10-05
BR122012023120B8 (pt)	2022-01-18
AU2002333220C1 (en)	2023-10-05
NO2014011I1 (no)	2014-05-13
RS52865B (sr)	2013-12-31
AU2006215994A9 (en)	2006-10-05
KR20060118020A (ko)	2006-11-17
LTC1436271I2 (lt)	2016-09-12
ATE386730T1 (de)	2008-03-15
US20180127389A1 (en)	2018-05-10
US20210276966A1 (en)	2021-09-09
AR066460A2 (es)	2009-08-19
CN1319958C (zh)	2007-06-06
DK1749818T3 (da)	2009-10-12
EP1749818A2 (fr)	2007-02-07
US9708280B2 (en)	2017-07-18
CA2462110A1 (fr)	2003-04-10
RS20120158A3 (en)	2013-10-31
CY1107924T1 (el)	2013-09-04
BR0212733B1 (pt)	2014-05-13
NO332355B1 (no)	2012-09-03
US8110567B2 (en)	2012-02-07
AR036659A1 (es)	2004-09-22
KR100842702B1 (ko)	2008-07-01
US20060084662A1 (en)	2006-04-20
KR20070103515A (ko)	2007-10-23
PT1749818E (pt)	2009-10-06
CY1110064T1 (el)	2015-01-14
US7683053B2 (en)	2010-03-23
ZA200401583B (en)	2005-05-25
US9090575B2 (en)	2015-07-28
EP1749818B1 (fr)	2009-09-02
JP2005505585A (ja)	2005-02-24
HUP0402313A2 (hu)	2005-02-28
US20110009423A1 (en)	2011-01-13
UA81749C2 (uk)	2008-02-11
SI1436271T1 (sl)	2008-06-30
NO20083446L (no)	2004-04-21
US20120302553A1 (en)	2012-11-29
HRP20040220A2 (en)	2005-02-28
MXPA04002959A (es)	2004-07-05
BR122012009534C8 (pt)	2021-05-25
ES2328725T3 (es)	2009-11-17
US8476279B2 (en)	2013-07-02
DE60225162D1 (de)	2008-04-03
PL368442A1 (pl)	2005-03-21
NL300652I2 (fr)	2016-01-18
CO5580746A2 (es)	2005-11-30
JP3955613B2 (ja)	2007-08-08
IS2578B (is)	2010-02-15
PL209253B1 (pl)	2011-08-31
JP3955614B2 (ja)	2007-08-08
WO2003029232A1 (fr)	2003-04-10
RS27704A (sr)	2006-10-27
AU2006215994A2 (en)	2006-10-05
PT1436271E (pt)	2008-04-10
EA007537B1 (ru)	2006-10-27
NO20041628L (no)	2004-04-21
CA2462110E (fr)	2003-04-10
NZ531556A (en)	2005-12-23
RS52326B (sr)	2012-12-31
EP1436271A1 (fr)	2004-07-14
EG25095A (en)	2011-08-17
US10844029B2 (en)	2020-11-24
JP2007031447A (ja)	2007-02-08
FR14C0033I2 (fr)	2014-11-14
BRPI0212733B8 (pt)	2021-05-25
BE2014C036I2 (fr)	2021-11-22
KR20040047886A (ko)	2004-06-05
DE60233608D1 (de)	2009-10-15
NL300652I1 (fr)	2016-01-18
HU230189B1 (hu)	2015-09-28
NO2014011I2 (no)	2015-08-31
PL210551B1 (pl)	2012-02-29
IS7164A (is)	2004-02-26
EP1436271B3 (fr)	2022-04-20
US20050014740A1 (en)	2005-01-20
US7148238B2 (en)	2006-12-12
DE60225162T3 (de)	2022-08-11
AU2002333220B2 (en)	2008-02-07
EA011096B1 (ru)	2008-12-30
EP1436271B1 (fr)	2008-02-20
US20060089368A1 (en)	2006-04-27
DK1436271T6 (da)	2022-06-27
JP3896116B2 (ja)	2007-03-22

Publication	Publication Date	Title
LU92397I2 (fr)	2014-05-12	Vortioxétine ou un sel d'addition d'acide de celui-ci pharmaceutiquement acceptable
NO2024019I1 (no)	2024-04-29	Lenvatinib eller et farmasøytisk akseptabelt salt derav eller et hydrat derav
LU93320I2 (fr)	2017-01-30	Everolimus ou un sel pharmaceutiquement acceptable de celui-ci
LU92520I2 (fr)	2015-11-02	Bédaquiline, ou son sel d'addition d'acide ou de base pharmaceutiquement acceptable, y compris le fumarate de bédaquiline
LU92943I2 (fr)	2016-03-14	Ceftolozane ou un sel pharmaceutiquement acceptable, en particulier un sel d'acide sulfurique (zerbaxa)
FR2817306B1 (fr)	2006-12-01	Systeme d'entrainement
EE200200716A (et)	2004-08-16	Ühendid Alzheimeri tõve käitluseks
FR2812203B1 (fr)	2003-01-03	Appareil d'aide a la ventilation d'un patient
MA27126A1 (fr)	2005-01-03	3'PROMEDICAMENTS DE 2'-DESOXY- β-L-NUCLEOSIDES
DE60044625D1 (de)	2010-08-12	Système d'assistance de conduire pour vehicules
LU92826I2 (fr)	2015-11-24	Lubiprostone, incluant les sels pharmaceutiquementacceptables, les esters ou les amides de la lubip rostone
IL161736A0 (en)	2005-11-20	Novel benzophenone derivatives or salts thereof
EP1293131A4 (fr)	2005-10-19	Agents therapeutiques pour la gorge
ECSP045162A (es)	2004-08-27	"composiciones farmaceuticas a base de derivados de azetidina"
FR2818979B1 (fr)	2003-05-30	Procede de preparation d'imidaclopride
EE200200554A (et)	2004-04-15	Galantamiini või selle farmatseutiliselt sobiva soola kasutamine
EP1314428A4 (fr)	2006-10-18	Preparations d'oct
ITMI20012197A0 (it)	2001-10-22	Sistema di ausilio all'arbitraggio di un incontro di calcio
GB0012123D0 (en)	2000-07-12	Alzheimer's disease assay
AU2002364885A1 (en)	2003-06-10	Alzheimer's disease model
FR2819984B1 (fr)	2003-09-05	Dispositif pour la preparation de racines d'endives destinees a la production de chicons
PL368419A1 (en)	2005-03-21	Novel $g(a)-oxygenated or $g(a)-thiolated carboxylic acid phenethylamide derivatives
MA25828A1 (fr)	2003-07-01	Procede de preparation d'oligomeres de galactomannanes
ITMI20000810A0 (it)	2000-04-12	Procedimento per la preparazione di 5'-acetilstavudina
FR2829806B3 (fr)	2003-07-25	Ensemble d'helice perfectionne